课题基金 / 基金详情

Gastro-intestinal microbes degrading dietary gluten

Gastro-intestinal microbes degrading dietary gluten
胃肠道微生物降解膳食麸质
批准号:
8279469
负责人:
Eva Josephine Helmerhorst
金额:
$42.27万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2015-05-31

项目摘要

项目成果

Eva Josephine Helmerhorst的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):胃肠道是各种微生物的主要储存库。定植微生物在促进宿主代谢过程和整体胃肠道健康方面的作用正得到越来越广泛的认可。我们实验室最近的工作表明,口腔中的细菌(胃肠道的入口)能够降解膳食面筋。麸质引起免疫反应和严重的临床条件的患者患有乳糜泻。这种疾病的基础是一种自身免疫性疾病,其中由谷蛋白衍生的细胞毒性肽引发宿主抗自身反应。患有明显的乳糜泻的患者患有胃肠病,并且处于营养不良、贫血、骨质疏松症和胃肠道恶性肿瘤如淋巴瘤和腺癌的风险中。为了避免麸质毒性,患者需要严格遵守无麸质饮食,这是目前唯一可用的治疗选择。然而,饮食限制方法需要终身承诺,并对患者造成重大负担。从口腔中发现天然谷蛋白降解微生物为寻求中和谷蛋白的有害影响开辟了一条有希望的新途径。本申请寻求探索常驻胃肠道微生物的蛋白水解活性,并研究它们将谷蛋白片段化为无毒肽的潜力。具体目标是:(1)鉴定牙菌斑和粪便样本中的谷蛋白降解微生物;(2)确定蛋白酶切割位点特异性并评估免疫原性麦醇溶蛋白区域的消除,并确定pH活性谱;(3)在T细胞增殖测定和腹腔疾病的体内模型中评估所选微生物和纯化酶制剂对麦醇溶蛋白的解毒作用;(4)鉴定、克隆和重组表达最有希望的酶的基因。通过胃肠道的天然定殖菌减少谷蛋白毒性将以益生菌或纯谷蛋白降解酶的应用的形式提供新的治疗前景。 公共卫生相关性:麸质是对麸质过敏的人和患有乳糜泻的患者不能耐受的蛋白质。一种有前途的方法,以减少面筋毒性是使用酶降解这些蛋白质成无毒片段。本申请寻求鉴定由来自人胃肠道的常驻微生物表达的谷蛋白中和酶。
英文摘要
DESCRIPTION (provided by applicant): The gastrointestinal tract is a major reservoir of a wide variety of microorganisms. The role of the colonizing microorganisms in contributing to host metabolic processes and overall gastrointestinal health is becoming more widely recognized. Recent work in our laboratory has revealed that bacteria residing in the oral cavity, the entrance to the gastrointestinal tract, are able to degrade dietary gluten. Glutens elicit immunologic reactions and serious clinical conditions in patients suffering from celiac disease. The basis of this disease is an auto-immune disorder in which a host-anti-self response is triggered by gluten-derived cytotoxic peptides. Patients with overt celiac disease suffer from gastroenteropathy and are at risk for malnutrition, anemia, osteoporosis and gastrointestinal malignancies such as lymphoma and adenocarcinoma. To avoid gluten toxicity, patients are required to adherence to a strict gluten-free diet, which is currently the only treatment option available. However, the dietary restriction approach requires a life-long commitment and represents a significant burden to the patient. The discovery of natural gluten degrading microorganisms from the oral cavity opens a promising new avenue in the quest to neutralize the deleterious effects of glutens. The current application seeks to explore the proteolytic activities of resident gastrointestinal microorganisms and study their potential to fragment gluten proteins into non-toxic peptides. The specific aims are: (1) To identify gluten-degrading microorganism(s) in dental plaque and fecal specimens; (2) To define protease cleavage site specificity and assess the abolishment of immunogenic gliadin regions, and to determine pH activity profiles; (3) To assess gliadin detoxification by selected microbes and purified enzyme preparations in a T-cell proliferation assay and in an in vivo model for celiac disease; (4) To characterize, clone and recombinantly express the gene(s) of the most promising enzyme(s). Reduction of gluten toxicity by natural colonizers of the gastrointestinal tract would offer novel treatment perspectives in the form of probiotics or applications of pure gluten-degrading enzymes. PUBLIC HEALTH RELEVANCE: Glutens are proteins which are not tolerated by people who are allergic to gluten and by patients suffering from celiac disease. A promising approach to reduce gluten toxicity is using enzymes to degrade these proteins into non-toxic fragments. The current application seeks to identify gluten-neutralizing enzymes expressed by resident microbes from the human gastrointestinal tract.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oral microbial enzymes for the treatment of celiac disease
  • 批准号:
    8509426
  • 项目类别:
  • 资助金额:
    $10.19万
  • 财政年份:
    2013
  • 负责人:
    Eva Josephine Helmerhorst
  • 依托单位:
Oral microbial enzymes for the treatment of celiac disease
  • 批准号:
    9275335
  • 项目类别:
  • 资助金额:
    $10.19万
  • 财政年份:
    2013
  • 负责人:
    Eva Josephine Helmerhorst
  • 依托单位:
Oral microbial enzymes for the treatment of celiac disease
  • 批准号:
    8681349
  • 项目类别:
  • 资助金额:
    $10.19万
  • 财政年份:
    2013
  • 负责人:
    Eva Josephine Helmerhorst
  • 依托单位:
Oral microbial enzymes for the treatment of celiac disease
  • 批准号:
    9067914
  • 项目类别:
  • 资助金额:
    $10.19万
  • 财政年份:
    2013
  • 负责人:
    Eva Josephine Helmerhorst
  • 依托单位:
海外基金